1
项与 NNC0560-0004 相关的临床试验A Phase I, Randomised, Double Blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Once-daily Oral Doses of NNC0560-0004 in Healthy Humans, With an Additional Open Label Single Dose Cohort of CYP2D6 Poor Metabolizers.
In this trial, medicine NNC0560-0004 given in capsule form will be compared to placebo in healthy volunteers.
Participants will either get NNC0560-0004 or placebo. Which treatment they get is decided by chance.
This is a first in human trial, which means that this is the first time that NNC0560-0004 is given to humans.
The study will last for about two weeks plus the screening period (approximately 42 days) which in all is about 8 weeks.
Women must be of non-childbearing potential thus you cannot take part if you are pregnant, can become pregnant, breast-feeding or plan to get pregnant during the study period.
100 项与 NNC0560-0004 相关的临床结果
100 项与 NNC0560-0004 相关的转化医学
100 项与 NNC0560-0004 相关的专利(医药)
100 项与 NNC0560-0004 相关的药物交易